In a major regulatory filing submitted to Indian stock exchanges today, June 8, 2026, Viyash Scientific Limited (formerly known as SeQuent Scientific Limited) announced a definitive international expansion aimed at dominating the high-margin European veterinary medicine market.
The Hyderabad-headquartered pharmaceutical conglomerate, recognized globally as an integrated leader across human and animal health, has formalized a binding agreement to fully absorb Italian pet care specialist BioForLife Italia s.r.l..
Transaction Structure & Financial Details
The cross-border acquisition is being executed via Viyash Scientific’s Ireland-based, step-down wholly-owned subsidiary, Alivira Animal Health Limited. Under the terms of the binding agreement, Alivira Ireland will acquire a 100% shareholding in the Milan-headquartered target entity.
he aggregate consideration for the transaction is valued at EUR 16.975 million (approximately ₹188 crores). The financial structure divides the cash layout into two clean tranches:
-
An immediate cash payment of EUR 15.0 million executable at the official transaction closing
-
A EUR 1.975 million structural balance maintained as deferred consideration, to be disbursed in compliance with specified transaction parameters
The transaction is expected to officially close during the second quarter of the 2027 fiscal year (Q2 FY27), subject to standard conditions precedent and statutory international approvals.
Strategic Rationale: Tapping the Premium European Pet Market
BioForLife Italia s.r.l. has built an established distribution network across Italy, specializing in the marketing, positioning, and logistics of specialized animal health and veterinary products tailored exclusively for companion animals. The company recorded robust commercial performance, tracking annual sales of approximately EUR 9.0 million for the calendar year 2025.
By absorbing BioForLife, Viyash Scientific secures a turnkey commercial platform inside one of Continental Europe’s most profitable companion care ecosystems. This integration drastically lowers traditional regulatory entry barriers, allowing Alivira’s wider veterinary formulations pipeline to quickly access European veterinary clinics, pharmacies, and premium retail networks.
Macro Corporate Trajectory
This acquisition represents another calculated step forward for Viyash Scientific following its successful institutional merger with SeQuent Scientific Limited. Curating a massive global footprint that spans over 150 countries with 15 state-of-the-art manufacturing plants, the company has consolidated its rank among the top 25 specialized animal health enterprises in the world.
The integration of BioForLife Italia shifts the company’s financial balance further toward the high-margin, recession-resilient companion care segment. This move insulates Viyash’s revenue streams from the price volatility often seen in the traditional bulk agricultural livestock sectors.
SEQUENT_Acquisition of BioForLife-June 8 2026
For further information regarding the company’s manufacturing footprint, financial statements, and regulatory compliance disclosures, stock market participants can review the official Viyash Scientific Investor Relations Portal.
